Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | cytochrome P450 reductase | 0.0417 | 1 | 1 |
Echinococcus multilocularis | methionine synthase reductase | 0.0258 | 0.553 | 0.422 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0417 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.016 | 0.2784 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0207 | 0.4112 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0258 | 0.553 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0417 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0417 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0417 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0417 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0417 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.016 | 0.2784 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0417 | 1 | 1 |
Echinococcus granulosus | geminin | 0.0205 | 0.4047 | 0.2303 |
Loa Loa (eye worm) | hypothetical protein | 0.0141 | 0.2266 | 0.2266 |
Entamoeba histolytica | type A flavoprotein, putative | 0.016 | 0.2784 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.037 | 0.8671 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0417 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0417 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0417 | 1 | 1 |
Trypanosoma cruzi | C-8 sterol isomerase, putative | 0.0396 | 0.94 | 0.9169 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0417 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0417 | 1 | 1 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.037 | 0.8671 | 0.8159 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.4047 | 0.2303 |
Loa Loa (eye worm) | hypothetical protein | 0.0202 | 0.398 | 0.398 |
Loa Loa (eye worm) | hypothetical protein | 0.0417 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.016 | 0.2784 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0258 | 0.553 | 0.422 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.4047 | 0.2303 |
Plasmodium vivax | flavodoxin domain containing protein | 0.037 | 0.8671 | 0.8159 |
Loa Loa (eye worm) | hypothetical protein | 0.0141 | 0.2266 | 0.2266 |
Loa Loa (eye worm) | flavodoxin family protein | 0.016 | 0.2784 | 0.2784 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0417 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0417 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0258 | 0.553 | 0.553 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0417 | 1 | 1 |
Treponema pallidum | flavodoxin | 0.016 | 0.2784 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0417 | 1 | 1 |
Leishmania major | C-8 sterol isomerase-like protein | 0.0396 | 0.94 | 0.9169 |
Leishmania major | p450 reductase, putative | 0.0417 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0417 | 1 | 1 |
Echinococcus multilocularis | geminin | 0.0205 | 0.4047 | 0.2303 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0417 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.021 | 0.4201 | 0.2502 |
Brugia malayi | FAD binding domain containing protein | 0.0258 | 0.553 | 0.553 |
Schistosoma mansoni | diflavin oxidoreductase | 0.0207 | 0.4112 | 0.2387 |
Brugia malayi | ERG2 and Sigma1 receptor like protein | 0.0396 | 0.94 | 0.94 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0207 | 0.4112 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.016 | 0.2784 | 0.5 |
Leishmania major | cytochrome P450 reductase, putative | 0.037 | 0.8671 | 0.8159 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.037 | 0.8671 | 0.5 |
Echinococcus granulosus | methionine synthase reductase | 0.0258 | 0.553 | 0.422 |
Trypanosoma brucei | C-8 sterol isomerase, putative | 0.0396 | 0.94 | 0.9169 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0417 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0396 | 0.94 | 0.94 |
Brugia malayi | flavodoxin family protein | 0.016 | 0.2784 | 0.2784 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.929 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.